This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
| Feature | MERCURY II |
|---|---|
| Title | Low Rectal Cancer Study (MERCURY II) |
| Status | UNKNOWN |
| Sponsor | Royal Marsden NHS Foundation Trust |
| Sponsor type | OTHER |
| Condition | Rectal cancer and related colorectal neoplasms |
2. Clinical Question
Population
Patients with low rectal cancer.
Intervention
The registry describes a single-arm study evaluating outcomes associated with surgical approaches.
Comparator
No comparator arm is registered.
Primary question
The study assessed CRM positivity rate and global quality of life after surgery.
3. Trial Design
MERCURY II was registered as a one-arm clinical study with 542 participants. Because the registry reports one arm, comparative randomized treatment-effect methods are not applicable.
| Design feature | Description |
|---|---|
| Number of arms | 1 |
| Enrollment | 542 |
| Study period | Start date: 2007-08-13; primary completion date: 2016-03-11 |
4. Endpoints
| Endpoint | Time Frame |
|---|---|
| To assess the rate of CRM positivity rate in low rectal cancer. | 4 years |
| To compare global quality of life at two years post surgery in patients according to plane of surgery with or without sphincter preservation. | 8 years |
5. Planned Analysis
The ClinicalTrials.gov record lists the primary endpoints but does not contain posted statistical analyses or results.
For a CRM positivity endpoint, statistical evaluation would typically focus on estimating the observed proportion of patients with a positive circumferential resection margin and describing uncertainty around that estimate. For quality-of-life outcomes measured over time, analysis would generally depend on the measurement scale, missing-data pattern, and prespecified comparison framework.
6. Statistical Methodology
This study illustrates analysis of observational surgical outcomes rather than a randomized treatment comparison. The main statistical considerations are estimation, precision, and appropriate handling of patient-reported outcomes.
Proportions and confidence intervals
A CRM positivity rate is a binary outcome summarized as the number of patients meeting the definition divided by the number evaluated. Confidence intervals describe uncertainty around the estimated rate.
Quality-of-life analysis
Quality-of-life endpoints require attention to the instrument used, follow-up timing, baseline values, and missing observations. Longitudinal patient-reported outcomes are often analyzed using methods that account for repeated measurements within individuals.
7. Statistical Methods Explained
Why is CRM positivity analyzed as a rate?
CRM positivity is a yes/no outcome. A proportion directly describes how frequently the outcome occurs in the evaluated population.
Why are confidence intervals important?
An observed percentage from a sample is an estimate. Confidence intervals communicate the uncertainty associated with that estimate.
Why is this not a hazard-ratio trial?
The registry does not describe a randomized time-to-event comparison. Hazard ratios are designed for comparing event rates over time between groups.
Why do quality-of-life outcomes need special methods?
Repeated assessments from the same patient are correlated, and missing assessments can affect interpretation.
Why does a single-arm design matter?
Without a comparator group, observed outcomes cannot directly estimate a treatment effect relative to another strategy.
8. Limitations
- The registry describes a single-arm study, limiting direct comparative interpretation.
- ClinicalTrials.gov does not report posted statistical analyses or numerical outcome results for MERCURY II.
- Quality-of-life interpretation depends on the measurement instrument and handling of missing follow-up assessments.
- Observed surgical outcomes may reflect patient selection, surgical expertise, and clinical practice context.
9. Why This Trial Matters Statistically
| Concept | Application |
|---|---|
| Proportion estimation | CRM positivity rate assessment |
| Patient-reported outcomes | Global quality-of-life evaluation |
| Missing data | Important consideration for longitudinal quality-of-life measures |
| Study design | Single-arm clinical investigation |